Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neuropsychiatr Dis Treat. 2008 Dec;4(6):1203-9.

Mycophenolate mofetil for myasthenia gravis: a clear and present controversy.

Author information

  • 1Department of Neurology, The University of Rochester, Rochester, New York, USA.

Abstract

Mycophenolate mofetil (MMF) has been used to treat myasthenia gravis (MG) for over 10 years. MMF's use in the MG population stems from its theoretical mechanism of action and the medical literature that supports its benefit in MG patients. Recently, two large, double-blinded, placebo-controlled, randomized clinical trials were initiated to study the effectiveness of MMF for MG. One of these studies found no benefit in taking MMF with 20 mg of prednisone as compared to taking prednisone alone, while the other study demonstrated no advantage in taking MMF against placebo during a 36-week prednisone taper. This article critically reviews the medical literature on MMF's use in MG and suggests further research avenues on this topic.

KEYWORDS:

CellCept; myasthenia gravis; mycophenolate mofetil

PMID:
19337460
[PubMed]
PMCID:
PMC2646649
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk